A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard

Modern Pathology

Volumn 26, Issue 11, 2013, Pages 1438-1450

  Won, Jennifer R ^a,b   Gao, Dongxia ^b   Chow, Christine ^b   Cheng, Jinjin ^b   Lau, Sherman Yh ^b   Ellis, Matthew J ^c   Perou, Charles M ^d   Bernard, Philip S ^e   Nielsen, Torsten O ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

basal like breast cancer; biomarker; gene expression profiling; immunohistochemistry; INPP4B; molecular subtype; nestin

Indexed keywords

BETA CRYSTALLIN; BIOLOGICAL MARKER; CALGRANULIN B; CK14 PROTEIN; CK17; CK5; CK6; CLAUDIN 4; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FASCIN; IMP3 PROTEIN; KI 67 ANTIGEN; MOESIN; NESTIN; NGFR PROTEIN; P CADHERIN; PPH3 PROTEIN; PROTEIN P16; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; STEM CELL FACTOR; TRIM29 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BASAL LIKE BREAST CANCER; GENE EXPRESSION PROFILING; GOLD STANDARD; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RISK ASSESSMENT; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; NESTIN; PHOSPHORIC MONOESTER HYDROLASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887085138     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.97     Document Type: Article

References (163)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
2. Geyer F, Marchio C, Reis-Filho J. The role of molecular analysis in breast cancer. Pathology 2009; 41:77-88.
3. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569. (Pubitemid 44200649)
4. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol 2005;205: 248-254.
5. Carey LA. Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. Clin Breast Cancer 2010;10:188-195.
6. Cummings MC, Chambers R, Simpson PT, et al. Molecular classification of breast cancer: is it time to pack up our microscopes? Pathology 2011;43:1-8.
7. Perou CM, Brresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol 2011;3:a003293.
8. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
9. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423. (Pubitemid 36842560)
10. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-3277.
11. Voduc D, Cheang MCU, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-1691.
12. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14:5158-5165.
13. Carey LA. Directed therapy of subtypes of triplenegative breast cancer. Oncologist 2010;15:49-56.
14. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374. (Pubitemid 39100473)
15. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010;15:61-70.
16. Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-1376. (Pubitemid 351413917)
17. Yehiely F, Moyano JV, Evans JR, et al. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 2006;12:537-544. (Pubitemid 44740239)
18. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-139. (Pubitemid 351538762)
19. Foulkes WD, Brunet J, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin ehigh/p27low/p53\+/glomeruloid-microvascular- proliferation\+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-835. (Pubitemid 38176880)
20. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005; 18:1321-1328. (Pubitemid 41348650)
21. Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle 2006;5:963-967.
22. Arnes JB, Begin LR, Stefansson I, et al. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin Pathol 2009;62:139-146.
23. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502. (Pubitemid 43854964)
24. Nalwoga H. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. Acta Pathol Microbiol Immunol Scandinavica 2008;116:515-525.
25. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol 2010;76:44-52.
26. Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011;24:157-167.
27. Bastien RR, Rodriguez-Lescure A, Ebbert MT, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012;5:44-56.
28. Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 2005;69:478-485.
29. Rakha EA, Putti TC, El-Rehim DMA, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506. (Pubitemid 43329336)
30. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008;123:236-240. (Pubitemid 351705215)
31. Choo JR, Nielsen TO. Biomarkers for basal-like breast cancer. Cancers 2010;2:1040-1065.
32. Toft DJ, Cryns VL. Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 2010;25:199-211.
33. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
34. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer. Clin Cancer Res 2010;16:5222-5232.
35. Graveel CR, DeGroot JD, Su Y, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009;106:12909-12914.
36. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-750.
37. Knudsen BS, Zhao P, Resau J, et al. A novel multipurpose monoclonal antibody for evaluating human c-met expression in preclinical and clinical settings. App Immunohisto Mol Morph 2009;17:57-67.
38. Moyano JV, Evans JR, Chen F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006;116: 261-270. (Pubitemid 43121811)
39. Sitterding SM, Wiseman WR, Schiller CL, et al. AlphaB-crystallin: a novel marker of invasive basallike and metaplastic breast carcinomas. Ann Diagn Pathol 2008;12:33-40.
40. Ivanov O, Chen F, Wiley E, et al. aB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2008;111:411-417.
41. Chan SK, Lui PCW, Tan PH, et al. Increased alpha-Bcrystallin expression in mammary metaplastic carcinomas. Histopathology 2011;59:247-255.
42. Hall PA, Todd CB, Hyland PL, et al. The septinbinding protein anillin is overexpressed in diverse human tumors. Clin Cancer Res 2005;11:6780-6786. (Pubitemid 41428731)
43. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001;19:3660-3668. (Pubitemid 32786278)
44. Tan EY, Yan M, Campo L, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 2009;100:405-411.
45. Pinilla S, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006;99:85-90. (Pubitemid 44168607)
46. Savage K, Lambros MBK, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007;13:90-101. (Pubitemid 46121857)
47. Liedtke C, Kersting C, Burger H, et al. Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol 2007;5:110-118.
48. Elsheikh SE, Green AR, Rakha EA, et al. Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 2008;99:327-334.
49. Patani N, Martin LA, Reis-Filho JS, et al. The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat 2012;131:1-15.
50. Savage K, Leung S, Todd S, et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat 2008;110:245-256. (Pubitemid 351793874)
51. Klingbeil P, Natrajan R, Everitt G, et al. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat 2009;120:95-109.
52. Ricardo S, Vieira AF, Gerhard R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011;64:937-946.
53. de Beça FF, Caetano P, Gerhard R, et al. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 2013;66:187-191.
54. Olsson E, Honeth G, Bendahl PO, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011;11: 418-431.
55. Yu P, Zhou L, Ke W, et al. Clinical significance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol 2010;136: 1283-1292.
56. Shah NG, Trivedi TI, Vora HH, et al. CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study. Tumori 2010;96:971-977.
57. Afify A, Purnell P, Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 2009;86:95-100.
58. Tsuda H, Morita D, Kimura M, et al. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 2005;96:48-53. (Pubitemid 40310025)
59. Azoulay S, Lae M, Freneaux P, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 2005;18:1623-1631. (Pubitemid 41670663)
60. Lanigan F, McKiernan E, Brennan DJ, et al. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 2009;124:2088-2097.
61. Kulka J, Szász A, Németh Z, et al. Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathol Oncol Res 2009;15:59-64.
62. Blanchard A, Skliris G, Watson P, et al. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 2009;454:647-656.
63. Voduc D, Nielsen TO, Cheang MC, et al. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum Pathol 2008;39: 1431-1437.
64. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005;47:458-466. (Pubitemid 41626723)
65. Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;447:688-694. (Pubitemid 41571183)
66. Paredes J, Lopes N, Milanezi F, et al. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 2007;450:73-80. (Pubitemid 46360747)
67. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996. (Pubitemid 35434844)
68. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30:1097-1104. (Pubitemid 44299342)
69. Liu ZB, Wu J, Ping B, et al. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple-negative phenotype. Tumori 2009;95: 53-62.
70. Sousa B, Paredes J, Milanezi F, et al. P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol 2010;25:963-974.
71. Shao MM, Zhang F, Meng G, et al. Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast. Histopathology 2011;59:264-273.
72. Martin V, Botta F, Zanellato E, et al. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol 2012;27: 785-792.
73. Cheang MCU, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 2006;24: 5637-5644. (Pubitemid 46631303)
74. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006;12:1168-1174. (Pubitemid 43342505)
75. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11611. (Pubitemid 37205983)
76. De Brot M, Rocha RM, Soares FA, et al. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. Pathology 2012;44:303-312.
77. Holm K, Grabau D, Lövgren K, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 2012;6:494-506.
78. Hussein YR, Sood AK, Bandyopadhyay S, et al. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol 2012;43:1638-1644.
79. Zhang H, Rakha E, Ball G, et al. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat 2009;121:41-51.
80. Tang XY, Umemura S, Tsukamoto H, et al. Overexpression of fatty acid binding protein-7 correlates with basal-like subtype of breast cancer. Pathol Res Pract 2010;206:98-101.
81. Alshareeda AT, Rakha EA, Nolan CC, et al. Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. Breast Cancer Res Treat 2012;134:519-529.
82. Yoder BJ, Tso E, Skacel M, et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005;11:186-192. (Pubitemid 40075794)
83. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12:1533-1539.
84. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008;68:989-997. (Pubitemid 351272216)
85. Wang J, Ray P, Sim M, et al. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-jB signaling. Oncogene 2012;31: 4798-4802.
86. Ray PS, Bagaria SP, Wang J, et al. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study. Ann Surg Oncol 2011;18:3839-3847.
87. Ricardo SAV, Milanezi F, Carvalho ST, et al. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 2007;60: 1001-1005. (Pubitemid 47441932)
88. Walter O, Prasad M, Lu S, et al. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Human Pathol 2009;40:1528-1533.
89. Sidoni A, Cartaginese F. IMP3 expression in triplenegative breast carcinoma. Hum Pathol 2010;41: 1355-1356.
90. Vranic S, Gurjeva O, Frkovic-Grazio S, et al. A proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast. App Immunohisto Mol Morph 2011;19:413-416.
91. Samanta S, Sharma V, Khan A, et al. Regulation of IMP3 by EGFR signaling and repression by ERb: implications for triple-negative breast cancer. Oncogene 2012;31:4689-4697.
92. Fedele CG, Ooms LM, Ho M, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 2010;107:22231-22236.
93. Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009;16:115-125.
94. Weigman VJ, Chao HH, Shabalin AA, et al. Basal-like breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 2012;133:865-880.
95. Lu S, Simin K, Khan A, et al. Analysis of integrin Beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res 2008;14:1050-1058. (Pubitemid 351302550)
96. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 2007;60:1006-1012. (Pubitemid 47441933)
97. Carpenter PM, Wang-Rodriguez J, Chan OTM, et al. Laminin 5 expression in metaplastic breast carcinomas. Am J Surg Pathol 2008;32:345-353. (Pubitemid 351398925)
98. Kwon SY, Chae SW, Wilczynski SP, et al. Laminin 332 expression in breast carcinoma. App Immunohisto Mol Morph 2012;20:159-164.
99. Garcia S, Dalès J, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-met and with proteomic basal-like phenotype. Human Pathol 2007;38:830-841. (Pubitemid 46726507)
100. Gastaldi S, Comoglio PM, Trusolino L. The met oncogene and basal-like breast cancer: another culprit to watch out for. Breast Cancer Res 2010;12:208.
101. Ponzo MG, Park M. The met receptor tyrosine kinase and basal breast cancer. Cell Cycle 2010;9:1043-1050.
102. Charafe-Jauffret E, Monville F, Bertucci F, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer 2007;121:1779-1785. (Pubitemid 47417297)
103. Wang CC, Liau JY, Lu YS, et al. Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition. Histopathology 2012;61:78-87.
104. Krü ger K, Stefansson I, Collett K, et al. Microvessel proliferation by co-expression of endothelial nestin and ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast 2013;22:282-288.
105. Li H, Cherukuri P, Li N, et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 2007;67:501-510. (Pubitemid 46192186)
106. Parry S, Savage K, Marchio C, et al. Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol 2008;61:1045-1050.
107. Piras F, Ionta M, Lai S, et al. Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer. Eur J Histochem 2011;55:e39-e45.
108. Liu C, Chen B, Zhu J, et al. Clinical implications for nestin protein expression in breast cancer. Cancer Sci 2009;101:815-819.
109. Reis-Filho JS, Steele D, Di Palma S, et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol 2006;19:307-319. (Pubitemid 43117617)
110. Popnikolov NK, Cavone SM, Schultz PM, et al. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol 2005;18:1535-1541. (Pubitemid 41670651)
111. Herschkowitz J, He X, Fan C, et al. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008;10:R75.
112. Subhawong AP, Subhawong T, Nassar H, et al. Most basal-like breast carcinomas demonstrate the same rb-/p16\+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009;33:163-175.
113. Bohn OL, Fuertes-Camilo M, Navarro L, et al. p16INK4a expression in basal-like breast carcinoma. Int J Clin Exp Pathol 2010;3:600-607.
114. Traub F, Mengel M, Lü ck H, et al. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 2006;99:185-191. (Pubitemid 44268266)
115. Alsner J, Jensen V, Kyndi M, et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008;47:600-607. (Pubitemid 351878460)
116. Manié E, Vincent-Salomon A, Lehmann-Che J, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009;69:663-671.
117. Chae BJ, Bae JS, Lee A, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009;39:217-224.
118. Matkovic B, Juretic A, Separovic V, et al. Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. Tumori 2008;94:838-844.
119. Arnes JB, Brunet J, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005; 11:4003-4011. (Pubitemid 40791563)
120. Potemski P, Kusinska R, Kubiak R, et al. Relationship of P-cadherin expression to basal phenotype of breast carcinoma. Polish J Pathol 2007;58:183-188. (Pubitemid 350144556)
121. Turashvili G, McKinney SE, Goktepe O, et al. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Mod Pathol 2010;24:64-81.
122. Liu N, Yu Q, Liu T, et al. P-cadherin expression and basal-like subtype in breast cancers. Med Oncol 2012;29:2606-2612.
123. Kuroda H, Ishida F, Nakai M, et al. Basal cytokeratin expression in relation to biological factors in breast cancer. Human Pathol 2008;39:1744-1750.
124. Baak J, Gudlaugsson E, Skaland I, et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 2009;115:241-254.
125. Skaland I, Janssen EAM, Gudlaugsson E, et al. The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph nodenegative breast cancer. Cell Oncol 2009;31:261-271.
126. Bossard C, Jarry A, Colombeix C, et al. Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol 2006;59:706-710. (Pubitemid 44048778)
127. Skaland I, Janssen EAM, Gudlaugsson E, et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 2007;20: 1307-1315. (Pubitemid 350126856)
128. Rocha R, Nunes C, Rocha G, et al. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry. Pathol Res Prac 2008;204:655-662.
129. Arai K, Takano S, Teratani T, et al. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 2008;8: 243-252. (Pubitemid 351881350)
130. Cross SS, Hamdy FC, Deloulme JC, et al. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005;46: 256-269. (Pubitemid 40343172)
131. Gonçalves A, Charafe-Jauffret E, Bertucci F, et al. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 2008;7: 1420-1433.
132. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110: 633-641. (Pubitemid 34988787)
133. Hao L, Zhang C, Qiu Y, et al. Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Letters 2007;253:34-42. (Pubitemid 46881198)
134. Liu Y, Tamimi RM, Collins LC, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: Results from the nurses' health study. Breast Cancer Res Treat 2011;129:175-184.
135. Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009;20:1639-1646.
136. Kusinska R, Kordek R, Pluciennik E, et al. Does vimentin help to delineate the so-called 'basal type breast cancer'? J Exp Clin Cancer Res 2009;28: 118-126.
137. Chen MH, Wai-Cheong Yip G, Tse GM, et al. Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters. Mod Pathol 2008;21:1183-1191.
138. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979;6:65-70.
139. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 2010;11:174-183.
140. Sheri A, Dowsett M. Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Ann Oncol 2012;23:x219-x227.
141. Williams DJ, Cohen C, Darrow M, et al. Proliferation (ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. App Immunohisto Mol Morph 2011;19: 431-436.
142. Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012;18:4465-4472.
143. Cheang MC, Voduc KD, Tu D, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012;18:2402-2412.
144. Crown J, O'Shaughnessy J, Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 2012;23(Suppl 6):vi56-vi65.
145. Miller TW, Rexer BN, Garrett JT, et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011;13:224-236.
146. Adamo B, Deal AM, Burrows E, et al. Phosphatidylinositol-3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res 2011;13: R125-R136.
147. Hakim S, Bertucci M, Conduit S, et al. Inositol polyphosphate phosphatases in human disease. Curr Top Microbiol Immunol 2012;362:247-314.
148. Balakrishnan A, Chaillet JR. Role of the inositol polyphosphate-4- phosphatase type II Inpp4b in the generation of ovarian teratomas. Dev Biol 2013;373:118-129.
149. Naylor TL, Greshock J, Wang Y, et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005;7:R1186-R1198.
150. Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-1040. (Pubitemid 44435537)
151. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
152. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992;52:5334-5341.
153. Ehrmann J, Kolár Z, Mokrý J. Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol 2005;58:222-223. (Pubitemid 40193814)
154. Kolar Z, Ehrmann J, Turashvili G, et al. A novel myoepithelial/progenitor cell marker in the breast? Virchows Archiv 2007;450:607-609. (Pubitemid 46676253)
155. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009;15:2302-2310.
156. Yuan Z, Ghosh D. Combining multiple biomarker models in logistic regression. Biometrics 2008;64: 431-439. (Pubitemid 351698860)
157. Bansal A, Pepe MS. When does combining markers improve classification performance and what are implications for practice? Stat Med 2013;32: 1877-1892.
158. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
159. Mehta RJ, Jain RK, Leung S, et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat 2012;131: 881-890.
160. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882-890. (Pubitemid 38657490)
161. Harrison J, Kulkarni K, Baguneid M, et al. Oxford Handbook of Key Clinical Evidence. Oxford University Press: New York, NY, USA, 2009.
162. Rakha E, Reis-Filho J, Ellis I. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010;120:293-308.
163. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-1438.